Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
City of Hope Medical Center
National Institutes of Health Clinical Center (CC)
Goethe University
Stanford University
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Bellicum Pharmaceuticals